Merck & Co., Inc. (NYSE:MRK) is identified as one of the Most Undervalued S&P 500 Stocks to Buy Right Now. Leerink Partners maintains a Buy rating with a $107 price target. Promising clinical trial results, particularly with the drug ivonescimab, show potential in treating lung cancers.

Ivonescimab offers durable benefits through VEGF-A antagonism, potentially avoiding common side effects seen with similar drugs like bevacizumab. Merck & Co., Inc. (NYSE:MRK) is a global healthcare company specializing in prescription medicines, vaccines, and animal health products.

While MRK shows investment potential, other AI stocks may offer greater upside and less downside risk. For those seeking an undervalued AI stock benefiting from Trump-era tariffs and the onshoring trend, consider exploring the best short-term AI stock for free in a detailed report.

Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Leerink Partners Maintained a Buy on Merck & Co (MRK)